Clinical Trial Update: Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA) [Phase 2]

View source ↗

Summary

Phase 2 study of STX-100 in renal transplant recipients with interstitial fibrosis and tubular atrophy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allograft Dysfunction

Drugs mentioned

• STX-100

Snippet

Sponsor: Stromedix, Inc. | Conditions: Chronic Allograft Dysfunction | Phase 2 | Status: WITHDRAWN